Camrelizumab-induced anaphylactic shock in an esophageal squamous cell carcinoma patient: A case report and review of literature

BACKGROUND: Camrelizumab (SHR-1210), an immune checkpoint inhibitor, is clinically used as a therapeutic option for various types of tumors. However, reports of adverse reactions associated with camrelizumab are gradually increasing. Anaphylactic shock due to camrelizumab has not been reported previ...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Kai, Bao, Jian-Feng, Wang, Tao, Yang, Hao, Xu, Bao-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254201/
https://www.ncbi.nlm.nih.gov/pubmed/35949858
http://dx.doi.org/10.12998/wjcc.v10.i18.6198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254201/
https://www.ncbi.nlm.nih.gov/pubmed/35949858
http://dx.doi.org/10.12998/wjcc.v10.i18.6198

Ejemplares similares